Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Evotec Receives Pre-Clinical Milestone with Boehringer Ingelheim

Published: Tuesday, December 10, 2013
Last Updated: Tuesday, December 10, 2013
Bookmark and Share
The milestone relates to the transition of an oncology molecule into pre-clinical development.

Evotec AG announced that its research alliance with Boehringer Ingelheim has reached a milestone in November triggering revenues of € 4.0 m to Evotec. 

Dr Mario Polywka, Chief Operating Officer of Evotec commented: “This is the twenty-first milestone achieved as part of our alliance with Boehringer Ingelheim and represents a third oncology compound transitioning into pre-clinical development of which one is already in Phase I clinical trials. Our collaboration with Boehringer Ingelheim continues to support Evotec’s overall strategy of building up a pipeline of assets of which we have interest in future upside.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Evotec and Padlock Therapeutics Extend Collaboration
Evotec and Padlock Therapeutics announce initial success and extension of long-term collaboration.
Friday, January 09, 2015
Evotec, Fraunhofer in Drug Discovery Collaboration
The exclusive, strategic collaboration will combine the relevant platforms of both organisations, focusing on several disease areas.
Tuesday, July 08, 2014
Evotec Enters Biology Collaboration with Probiodrug
Evotec will setup and validate assays to support the pre-clinical and clinical development of QC inhibitors in Alzheimer’s disease.
Thursday, November 29, 2012
Evotec Receives Pre-clinical Milestone Payment
Evotec AG announces that its research alliance with Boehringer Ingelheim has achieved a milestone triggering a payment of EUR 4 million to Evotec.
Friday, August 19, 2011
Evotec Starts Phase II Clinical Studies in Treatment-Resistant Depression
The proof-of-concept Phase II trial will study the safety and tolerability of EVT 101 while also exploring the efficacy of this intervention.
Thursday, July 01, 2010
Evotec Reports Progress in Product Development in Treatment-Resistant Depression in its Alliance with Roche
Company completion its first-in-man study with EVT 103 and receives a positive feedback from the FDA to initiate Phase II with EVT 101.
Thursday, March 11, 2010
Evotec Extends Medicinal Chemistry Collaboration with Ono Pharmaceutical
Ono to access Evotec’s ion channel drug discovery platform and expertise and Evotec to receive research funding and milestone payments.
Monday, October 19, 2009
Evotec Starts Phase I with EVT 103, an NR2B-selective NMDA Receptor Antagonist
EVT 103 is currently planned to enter clinical development for treatment-resistant depression in collaboration with Roche.
Wednesday, September 09, 2009
Evotec Announces the Successful Completion of the First Phase I Study with EVT 401
The double-blind, placebo controlled study showed that the compound was safe and well tolerated without any serious adverse events.
Friday, July 10, 2009
Evotec Acquires Zebrafish Screening Operations of Summit Corporation
The acquisition against £ 0.5 million cash in 2009 expected to add approximately £ 1.5 million revenues in 2010.
Friday, May 08, 2009
Evotec Reports Results of Phase II Proof-of-Concept Study with EVT 302
Study fails to demonstrate any significant improvement in the quit rate compared with placebo.
Monday, April 20, 2009
Evotec Presents its Fragment Screening Technology at Two Key Conferences
Presentations will be given at Screening, MedChem and ADMET Europe and at the Molecular Medicine Tri-Conference.
Thursday, February 19, 2009
Evotec Reports Phase I Safety Data from Tyramine Interaction Study with EVT 302
The study was undertaken to determine potential safety advantages of EVT 302 versus non-selective MAO inhibitors and less selective MAO-B inhibitors.
Monday, November 03, 2008
Evotec Announces Phase I Initiation with P2X7 Antagonist
P2X7 receptor antagonism may provide a novel approach to the treatment of rheumatoid arthritis and other inflammatory conditions.
Friday, October 10, 2008
Evotec’s EVT 101 Well Tolerated in Four Week Higher Repeat Dose Safety Study
The study showed in both young and elderly subjects that EVT 101 was well tolerated up to the highest dose tested.
Friday, July 04, 2008
Scientific News
Lung Repair and Regeneration Gene Discovered
New role for hedgehog gene offers better understanding of lung disease.
New Gene Therapy for Vision Loss From a Mitochondrial Disease
NIH-funded study shows success in targeting mitochondrial DNA in mice.
Self-Propelled Powder to Stop Bleeding
UBC researchers have created the first self-propelled particles capable of delivering coagulants against the flow of blood to treat severe bleeding, a potentially huge advancement in trauma care.
Tension Helps Heart Cells Develop Normally in the Lab
Stanford engineers have uncovered the important role tension plays in growing heart cells out of the body.
Controlling Body Temperature in Response to 'Fight or Flight'
New research in The FASEB Journal suggests that blocking TRPV1 protein causes an increased release of noradrenaline, leading to an increase in core body temperatures.
Inroads Against Leukaemia
Potential for halting disease in molecule isolated from sea sponges.
Researchers Disguise Drugs As Platelets to Target Cancer
Researchers have for the first time developed a technique that coats anticancer drugs in membranes made from a patient’s own platelets.
A Fundamental Protection Mechanism Against Formalin In Mammals is Revealed
Formaldehyde, or formalin, is well known to all of us as a common chemical used in many industrial processes and also as a preservative, remarkably we also produce formaldehyde in our bodies.
Drug Used To Treat HIV Linked to Lower Bone Mass in Newborns
NIH study finds mothers’ use of tenofovir tied to lower bone mineral content in babies.
Bone Risks Linked to Genetic Variants
A large-scale genomic study uncovered novel genetic variants and led researchers to an unexpected gene that affects bone density and fracture risk.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos